Analysts think VERV stock price could increase by 501%
May 14, 2025, 11:25 AM
52.16%
What does VERV do
Verve Therapeutics, based in Boston, focuses on gene editing for cardiovascular diseases, employing 255 staff and going public on June 17, 2021. Its lead programs, VERVE-101, VERVE-102, and VERVE-201, target LDL-C-related genes.
9 analysts think VERV stock price will increase by 500.72%. The current median analyst target is $24.99 compared to a current stock price of $4.16. The lowest analysts target is $15.15 and the highest analyst target is $40.95.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
